Drug intelligence / Profile preview

angiotensin-(1-9) retro-enantiomer

Development stage
Preclinical
Lead developer
Pontificia Universidad Católica de Chile
Modality
Peptides
Administration
Subcutaneous
01

Overview

Angiotensin-(1-9) retro-enantiomer is a synthetic peptide biologic designed as a protease-resistant analog of the naturally occurring angiotensin-(1-9) peptide. It is synthesized using non-natural D-amino acids in a reversed sequence (retro-inverso) compared to the original L-peptide, which significantly enhances its chemical stability and extends its plasma half-life while maintaining biological activity. The drug acts as an agonist of the angiotensin type 2 receptor (AT2R), functioning within the counter-regulatory arm of the renin-angiotensin system. Preclinical studies have demonstrated its efficacy in preventing hypertension, cardiac hypertrophy, and diastolic dysfunction, particularly in models of heart failure with preserved ejection fraction (HFpEF). It also reduces pro-inflammatory macrophage infiltration in the myocardium and improves glucose tolerance.

Other names
retro-enantiomer of angiotensin-(1-9)Ang-(1-9) retro-enantiomer
02

Targets

AGTR2 (AT2)

Beyond the preview

Go deeper on angiotensin-(1-9) retro-enantiomer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on angiotensin-(1-9) retro-enantiomer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call